Pharming Group N.V. PHAR
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 366.48M | 369.49M | 376.13M | 362.27M | 339.84M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 366.48M | 369.49M | 376.13M | 362.27M | 339.84M |
| Cost of Revenue | 49.39M | 43.82M | 45.50M | 36.58M | 36.33M |
| Gross Profit | 317.09M | 325.67M | 330.63M | 325.70M | 303.51M |
| SG&A Expenses | 182.80M | 190.84M | 202.36M | 198.25M | 199.15M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -2.22M | -2.65M | -2.65M | -2.45M | -3.15M |
| Total Operating Expenses | 341.13M | 334.60M | 343.38M | 320.82M | 320.19M |
| Operating Income | 25.35M | 34.89M | 32.76M | 41.46M | 19.64M |
| Income Before Tax | 15.84M | 19.88M | 12.85M | 14.73M | 3.48M |
| Income Tax Expenses | 6.54M | 7.67M | 10.31M | 14.66M | 12.00M |
| Earnings from Continuing Operations | 9.30 | 12.21 | 2.54 | 0.07 | -8.51 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 0.00 | 144.00K | 313.00K | 313.00K | 313.00K |
| Net Income | 9.30M | 12.36M | 2.85M | 382.00K | -8.20M |
| EBIT | 25.35M | 34.89M | 32.76M | 41.46M | 19.64M |
| EBITDA | 37.24M | 46.64M | 43.97M | 57.17M | 35.62M |
| EPS Basic | 0.02 | 0.02 | 0.01 | 0.00 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| EPS Diluted | 0.02 | 0.02 | 0.01 | 0.00 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| Average Basic Shares Outstanding | 2.58B | 2.60B | 2.52B | 2.60B | 2.61B |
| Average Diluted Shares Outstanding | 2.67B | 2.69B | 2.61B | 2.60B | 2.61B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |